

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/109001 A1

(51) International Patent Classification:

C07D 239/84 (2006.01) A61P 35/00 (2006.01)
C07D 401/12 (2006.01) A61K 31/519 (2006.01)
C07D 471/04 (2006.01)

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2021/059678

(22) International Filing Date:

17 November 2021 (17.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/115,496 18 November 2020 (18.11.2020) US
63/185,846 07 May 2021 (07.05.2021) US

(71) Applicant: **DECIPHERA PHARMACEUTICALS, LLC** [US/US]; 200 Smith Street, Waltham, Massachusetts 02451 (US).

(72) Inventors: **FLYNN, Daniel L.**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **KEARNEY, Patrick**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **ZWICKER, Jeffery**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **AL-ANI, Gada**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **JAVED, Salim**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **AHN, Yu Mi**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **STOLTZ, Kristen**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US). **LEBOURDONNEC, Bertrand**; c/o 200 Smith Street, Waltham, Massachusetts 02451 (US).

(74) Agent: **GUTIERREZ, Gregory Daniel** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor, Boston, Massachusetts 02210 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF



(57) Abstract: Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.



WO 2022/109001 A1